Press-release for stocks related to therapy for SNYNF

tags : Therapy symbols : SNYNF

save search

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-22 (Crawled : 22:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| Email alert Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K

Health Technology

| Email alert Add to watchlist
genetic cell research therapy

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M

Health Technology

| -5.62% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -5.95% | O: 1.06% H: 0.0% C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M

Health Technology

| -8.19% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -3.73% | O: 0.42% H: 0.0% C: 0.0%
fda cancer blood therapy

FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $30.06 -2.4% 0.0% 1.4M

Health Technology

| -1.02% | O: 0.33% H: 0.13% C: -1.51%
JNJ | News | $149.12 0.82% 0.0% 9.3M

Health Technology

| -5.77% | O: 0.2% H: 0.08% C: -1.14%
ABT | News | $107.07 -0.2% 0.0% 4.9M

Health Technology

| -5.59% | O: 1.71% H: 0.36% C: -2.52%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.43% | O: -0.81% H: 0.0% C: 0.0%
fda rare first disease therapy

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510

Health Technology

| -5.41% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | News | $136.2 -4.19% 1.7K

Health Technology

| 9.24% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| -6.69% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.535 -4.38% 3.5K

Manufacturing

| 27.56% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | News | $9.5 -1.11% 1M

Manufacturing

| -14.3% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.36 0.91% -0.52% 1.6M

Health Technology

| -9.36% | O: -0.2% H: 0.14% C: -0.48%
NVS | News | $95.12 0.81% -1.18% 2.4M

Health Technology

| -7.6% | O: -0.06% H: 0.46% C: 0.29%
GSK | News | $40.59 2.11% -0.36% 3.8M

Health Technology

| -3.22% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $731.33 0.69% 0.0% 2.3M

Health Technology

| -1.95% | O: 2.37% H: 1.51% C: 0.79%
BMY | $49.14 0.43% 0.0% 7.9M

Health Technology

| -3.48% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $167.89 0.89% 0.0% 5.6M

Health Technology

| -4.79% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -1.81% | O: 1.67% H: 0.0% C: 0.0%
AZN | News | $70.12 2.29% 2.24% 4.8M

Health Technology

| 7.74% | O: -2.81% H: 2.08% C: 1.38%
AMGN | News | $271.98 1.13% 1.12% 2.1M

Health Technology

| -4.07% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 2.49% | O: 1.16% H: 1.48% C: 0.89%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| 1.35% | O: 1.86% H: 0.0% C: 0.0%
potential therapy show

FDA Decisions: Takeda's Immunoglobulin Therapy Approved for CDIP
Published: 2024-02-02 (Crawled : 17:00) - biospace.com/
PRGO | $30.06 -2.4% 0.0% 1.4M

Health Technology

| -6.88% | O: -0.53% H: 1.28% C: 0.53%
JNJ | News | $149.12 0.82% 0.0% 9.3M

Health Technology

| -5.66% | O: -0.15% H: 0.0% C: 0.0%
ABT | News | $107.07 -0.2% 0.0% 4.9M

Health Technology

| -6.48% | O: -0.57% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.51% | O: -0.93% H: 0.0% C: 0.0%
fda approved therapy

Global Iron Deficiency Anemia Therapy Market Report 2024
Published: 2024-02-02 (Crawled : 04:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -4.51% | O: -0.93% H: 0.0% C: 0.0%
report anemia global therapy market

AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -10.78% | O: -1.83% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M

Health Technology

| 15.25% | O: 0.77% H: 0.17% C: -1.65%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -10.44% | O: 0.45% H: 0.06% C: -0.5%
RGNX | $15.68 -0.06% -0.06% 440K

Health Technology

| 2.42% | O: -0.13% H: 0.0% C: -7.15%
ADVM | News | $11.34 -0.27% 170K

Health Technology

| 1305.2% | O: -0.69% H: 2.32% C: -0.12%
therapy growth study market

Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.87% | O: 0.28% H: 0.0% C: -1.32%
LLY | News | $731.33 0.69% 0.0% 2.3M

Health Technology

| 25.76% | O: 0.08% H: 0.81% C: -0.19%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -6.13% | O: 0.52% H: 0.72% C: -0.34%
INCY | $51.92 -0.82% -0.83% 1.8M

Health Technology

| -17.17% | O: 0.35% H: 1.07% C: -0.27%
candidate tumors collaboration trial advanced china therapy

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| -5.12% | O: -0.08% H: 0.0% C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K

Health Technology

| -14.39% | O: 0.67% H: 1.46% C: 0.08%
bnt323 fda candidate cancer designation therapy

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -0.54% | O: 0.5% H: 1.67% C: 0.1%
SNY | News | $47.125 1.78% 1.75% 2.1M

Health Technology

| 0.14% | O: 2.15% H: 0.0% C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi

FDA Greenlights First Therapy for Rare Cancer of the Nasopharynx
Published: 2023-10-30 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology